The Effect of High-Intensity Interval Training on Health Indicators in Women with Non-Alcoholic Fatty Liver Disease

Effects of Eight Weeks of High-Intensity Interval Training on Inflammatory Markers in Women with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250901067078N1

Enrollment

Registered

2025-09-25

Start date

2024-09-24

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Alcoholic Fatty Liver Disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Control group:The control group did not receive any exercise or training intervention and continued their usual daily activities. Intervention 2: Intervention group: The intervention g

Eligibility

Sex/Gender

Female

Age

30 Years to 50 Years

Inclusion criteria

Inclusion criteria: Female gender Patients with non-alcoholic fatty liver disease (grade 1 or 2, confirmed by ultrasound and a physician) Overweight or obesity (body mass index between 25 and 35) No history of using liver-related or metabolic medications

Exclusion criteria

Exclusion criteria: Regular physical activity during the past three months Occurrence of medical problems or sports injuries during the study Presence of specific diseases or use of special medications (cardiovascular, respiratory, renal, metabolic diseases, or cancer) Absence from more than three training sessions

Design outcomes

Primary

Measure	Time frame
Interleukin-6 (IL-6). Timepoint: Pre- and post-intervention. Method of measurement: Serum interleukin-6 (IL-6) concentration was measured using the Immulite IL-6 kit and an immunochemical method based on the Immulite 2000 system.;C-Reactive Protein. Timepoint: Pre- and post-intervention. Method of measurement: C-reactive protein (CRP) levels were measured using the CRP-H917-S kit manufactured by Delta Pars Company and the latex immunoturbidimetric method.;Cortisol. Timepoint: Pre- and post-intervention. Method of measurement: Cortisol levels were measured using a fully automatic IMMULITE 2000XPi device. This device employs the electrochemiluminescence chemistry method. The kits used were specifically designed for this device and in accordance with international standards.	—

Measure

Time frame

Interleukin-6 (IL-6). Timepoint: Pre- and post-intervention. Method of measurement: Serum interleukin-6 (IL-6) concentration was measured using the Immulite IL-6 kit and an immunochemical method based on the Immulite 2000 system.;C-Reactive Protein. Timepoint: Pre- and post-intervention. Method of measurement: C-reactive protein (CRP) levels were measured using the CRP-H917-S kit manufactured by Delta Pars Company and the latex immunoturbidimetric method.;Cortisol. Timepoint: Pre- and post-intervention. Method of measurement: Cortisol levels were measured using a fully automatic IMMULITE 2000XPi device. This device employs the electrochemiluminescence chemistry method. The kits used were specifically designed for this device and in accordance with international standards.

—

Secondary

Measure	Time frame
Body composition. Timepoint: Pre- and post-intervention. Method of measurement: Measurements were performed using scales, a stadiometer, the body mass index (BMI), and a body composition assessment device.;Lipid profile. Timepoint: Pre- and post-intervention. Method of measurement: Measurements were performed using the respective kits and automated analyzers.;Liver enzymes. Timepoint: Pre- and post-intervention. Method of measurement: Measurements were performed using the respective kits and automated analyzers.;Fasting blood insulin. Timepoint: ??? ? ?? ?? ??????. Method of measurement: Fasting insulin levels were measured using a human insulin enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer’s instructions.;Fasting blood glucose. Timepoint: Pre- and post-intervention. Method of measurement: Measurements were performed using a glucose kit and automated analyzers.;Maximal aerobic capacity. Timepoint: Pre- and post-intervention. Method of measurement: Shuttle Run Test.	—

Measure

Time frame

Body composition. Timepoint: Pre- and post-intervention. Method of measurement: Measurements were performed using scales, a stadiometer, the body mass index (BMI), and a body composition assessment device.;Lipid profile. Timepoint: Pre- and post-intervention. Method of measurement: Measurements were performed using the respective kits and automated analyzers.;Liver enzymes. Timepoint: Pre- and post-intervention. Method of measurement: Measurements were performed using the respective kits and automated analyzers.;Fasting blood insulin. Timepoint: ??? ? ?? ?? ??????. Method of measurement: Fasting insulin levels were measured using a human insulin enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer’s instructions.;Fasting blood glucose. Timepoint: Pre- and post-intervention. Method of measurement: Measurements were performed using a glucose kit and automated analyzers.;Maximal aerobic capacity. Timepoint: Pre- and post-intervention. Method of measurement: Shuttle Run Test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Abbas Monazami

Razi University of Kermanshah

MONAZZAMI.AMIRABBAS@gmail.com+98 83 3427 7605

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026